| Event Information |
 |
 March 31, 2005 | 5:30-7:30 PM | Goethe-Institute |
| Presentation and Discussion |
|
| Topic: |
"The Dark Side of Biotechnology" |
|
| Description: |
Current advances in biotechnology and human genetics promise to lead to major changes in healthcare, but they also raise the specter of possible malevolent uses. As a result of these changes we are at a key stage in human evolution, and the different ways this is likely to be viewed in Eastern and Western cultures could significantly destabilize society.
Dr. Charles Cantor is Chief Scientific Officer and Member, Board of Directors, at SEQUENOM, Inc., a leader in studying genetic differences among people. He is founder in 2002 and member, Board of Directors, of SelectX Pharmaceuticals, a drug discovery company based in the Boston area. He is also the director of the Center for Advanced Biotechnology at Boston University, and professor of Biomedical Engineering.
Dr. Cantor has held positions at Columbia University and University of California at Berkeley, and was also director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. He has published more than 360 peer-reviewed articles, has been granted more than 60 patents, and co-authored a three-volume textbook on Biophysical Chemistry and the first textbook on Genomics: The Science and Technology of the Human Genome Project.
He sits on the advisory boards of more than a dozen international companies, is a member of a several government advisory boards, and is a member of the National Academy of Sciences. |
|
| Speaker: |
Dr. Charles R. Cantor |
|
| Location: |
Goethe-Institute
170 Beacon Street, Boston
(Parking is available in the Boston Common garage) |
| Time: |
5:30 p.m. to 6:00 p.m. - Registration and Cocktails
6:00 p.m. to 7:30 p.m. - Presentation |
| Fee: |
$20 - Members and $30 - Non-Members |
| RSVP: |
Pre-registration is required by March 29, 2005.
Questions can be directed to GABC via email or call us at (617) 437-6588.
|
|
